Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (March 2021)
15 slides from Harrow's investor presentation, Mar 8, 2021
Slide 1: Corporate Presentation March 2021
HARROW Corporate Presentation March 2021
Slide 2: Safe Harbor
HARROW Safe Harbor This presentation contains express “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If under
Slide 3: Harrow is a growing leader in the U.S. ophthalmic healthcare market
HARROW > Harrow is a growing leader in the U.S. ophthalmic healthcare market. > Harrow became commercial in 2014; 149% eyecare revenue CAGR through 2019. > We've built a strong market position by selling high-value compounded drugs to institutions, which now includes about 10,000 doctors, hospitals
Slide 4: Traditional Pharmaceutical Value Chain
Traditional Pharmaceutical Value Chain On Ah oe MD/Hospital PRODUCTION PHARMACY INSURERS WHOLESALERS PHARMACY Prescription BENEFIT RETAILERS MANAGERS MD OFFICE, HOSPITAL OR ASC > Layers of middle-men thrive. > “Tiered” formularies and layers of intermediaries “feed” an opaque system. > “Discount car
Slide 5: Harrow's Simple Approach
Harrow’s Simple Approach Nationwide PATIENT entices Production and PAYMENT w Dispensing at Harrow-owned MD OFFICE, Facilities HOSPITAL OR ASC >» Cash-pay focused. >» No pharmacy benefit managers (PBMs), wholesalers or distribution “middlemen.” » No prior authorizations, formulary rejections, rebates
Slide 6: Imprimis Rx
Imprimis Reo > The leading FDA-registered cGMP ophthalmic pharmaceutical drug compounder. > Fully-integrated national sales and customer service teams and an efficient and scalable national distribution platform. > Ophthalmic surgical and chronic eyecare markets are large and growing: > 16+ million
Slide 7: Harrow Health Pharmaceutical Innovation Pipeline
Harrow Health Pharmaceutical Innovation Pipeline* > By partnering with doctors, Harrow has developed compounded products to address unmet patient needs, both large and small, helping eyecare professionals take care of their patients. Pre- R&D Stability Clinical Commercial Formulation Studies Evaluat
Slide 8: Visionology
€ visionology > Direct-to-consumer eyecare subsidiary of Harrow founded in 2020. > Focused on helping patients manage chronic eye disease using a simple and seamless user experience that was designed after 1,200 consumer interviews. » Regional launch targeted for first half of 2021. >» Leverage our
Slide 9: Annual Revenues, Gross Margin and Assets
Annual Revenues, Gross Margin and Assets (Revenues and Assets in Thousands) 70.4% $59,085 $57,474 $51,165 $49,451 $48,871 $41,372 34.2: $27,247 $26,774 $23,917 $19,942 $14,131 $10,242 $9,716 $1,660 2014 2015 2016 2017 2018 2019 2020 Consolidated Revenues (0 Assets ME Gross Margin HARROW coy
Slide 10: Profit Performance and Expense Discipline
Profit Performance and Expense Discipline (Dollars in Thousands) 2014 2015 2016 2017 2018 2019 2020 $5,700 $4,600 S500) 150% $7,000) ’ 25% 73% 77% 70% $(10,000) $(10,000) ME Adjusted E(L)BITDA HARROW HE «Operating Expense as a % of Revenue
Slide 11: COVID-19 Revenue and Profit Recovery
COVID-19 Revenue and Profit Recovery (Quarterly Revenues and Adjusted E(L)BITDA in Thousands) $14,400 $14,600 Mandated limitations on elective surgeries $12,600 $11,800 $1,700) HARROW HE Consolidated Revenues [IE Adjusted E(L)BITDA HEALTH INC.
Slide 12: Carve-Outs Contribute $57M to Harrow Health's Balance Sheet
Carve-Outs Contribute $57M* to Harrow Health’s Balance Sheet * Orphan-disease focused pharmaceutical company with a growing pipeline. Harrow Health owns 3.5M shares of Eton common stock (-15%). Valued at approximately $28,500,000 following IPO in November 2018 (ETON). elon PHARMACEUTICALS Clinical-s
Slide 13: Harrow Health Drug Candidate Royalty Pipeline
Harrow Health Drug Candidate Royalty Pipeline > Harrow Health owns royalty rights on out-licensed drug candidates in clinical development at both Surface Ophthalmics (4% royalty) and Melt Pharmaceuticals (5% royalty). > The markets for Surface’s and Melt’s drug candidates are in the billions of doll
Slide 14: Positioned to become a significant eyecare-focused healthcare company
HARROW > Positioned to become a significant eyecare-focused healthcare company. > We expect revenues to exceed $100M within the next few years. > Positioned to capture significant income on incremental revenue growth. > We believe we have the resources to finance the next stage of development, which
Slide 15: Contact
HARROW 102 Woodmont Blvd. Ste 610 Nashville, Tennessee 37205 www.Harrowlnc.com Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com Direct: 615-733-4737